US WorldMeds, LLC
4010 Dupont Circle, Suite 700
21 articles with US WorldMeds, LLC
Zimhi is indicated for use in both adults and children in the event of an emergency. It is to be given right away and does not take the place of emergency care.
US WorldMeds Launches GELX® ORAL GEL, a Zinc-Taurine Bioactive Barrier Therapy for Oral Mucositis Caused by Cancer Treatment
US WorldMeds, LLC announced the launch of GELX® ORAL GEL, a Zinc-Taurine bioactive barrier therapy for the management and relief of oral pain associated with oral mucositis.
Supernus Pharmaceuticals, Inc., a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, announced that the Company entered into a definitive agreement under which Supernus will acquire the CNS portfolio of US WorldMeds, a privately-held biopharmaceutical company.
Fighting America's Opioid Crisis: Physicians And Consumers Believe Lack Of Education Around How To Discontinue Opioids Is A Huge Barrier
In a national survey, physicians and consumers agree that fear of opioid withdrawal is keeping patients from getting off of opioids
FDA approves the reintroduction of Zelnorm™ (tegaserod) for Irritable Bowel Syndrome with Constipation (IBS-C) in women under 65
Zelnorm works differently than other prescription treatments for IBS-C by inducing intestinal contraction and relaxation.
As opioid lawsuits continue to wind through the courts, some drugmakers are focused on developing treatments for opioid addiction.
In a 99 to 1 vote, the Senate passed the bill that looks to cut down on the flow of illegal narcotics entering the United States through the mail, as well as taking aim at the abuse of prescription opioid medication – a problem that has grown to an epidemic in the United States.
US WorldMeds And Salix Pharmaceuticals To Highlight Clinical Data For Opioid Withdrawal Treatment LUCEMYRA™ (lofexidine) At 2018 PAINWeek Conference
Product Theater, Three Posters and Oral Poster Presentation to be Featured
First and only FDA-approved, non-opioid medication indicated for mitigation of opioid withdrawal symptoms is now available for prescription
Camargo Congratulates US WorldMeds on Obtaining FDA Approval for the First Non-Opioid Medicine for the Management of Opioid Withdrawal Symptoms
Camargo Pharmaceutical Services, LLC congratulates US WorldMeds, LLC, on obtaining US Food and Drug Administration (FDA) approval for LUCEMYRA™ (lofexidine) tablets
U.S. Food and Drug Administration approved a new treatment to help patients manage withdrawal symptoms from opioid addiction.
FDA Advisory Committee Votes in Favor of LUCEMYRA™ (lofexidine) for the Mitigation of Opioid Withdrawal Symptoms
US WorldMeds announced that the US Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee voted 11 to 1 to recommend approval of lofexidine for mitigating opioid withdrawal symptoms.
US WorldMeds, LLC Release: New Clinical Trial To Study The Use Of MYOBLOC® Injections Into The Salivary Glands To Treat Sialorrhea (Drooling)
US WorldMeds, LLC Release: New Clinical Trial Investigates APOKYN for Treating Debilitating Morning Akinesia in Parkinson’s Disease Patients
US WorldMeds, LLC Completes Phase III Trial of Lofexidine for Treatment of Opiate Withdrawal Symptoms
US WorldMeds, LLC Completes Development of Instantaneous Reconstitution Dantrolene Sodium for Injection Product